세계의 고지혈증 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)
Global Hyperlipidemia Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
상품코드:1820560
리서치사:Value Market Research
발행일:2025년 08월
페이지 정보:영문 156 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 고지혈증 치료제 시장은 상당한 성장을 이루었으며, 2024년 261억 달러에서 2033년에는 363억 3,000만 달러에 달할 것으로 예측됩니다. 2025년부터 2033년까지 연평균 성장률(CAGR) 3.74%로 성장할 것으로 예측됩니다.
고지혈증 치료제 시장은 전 세계적으로 심혈관질환 및 대사 이상 유병률 증가에 힘입어 큰 폭으로 확대될 것으로 예상됩니다. PCSK9 억제제, RNA 기반 치료제, 신규 저분자 화합물 등 지질저하 치료제의 발전으로 효능과 안전성 프로파일이 개선되고 있습니다. 앞으로의 성장을 뒷받침하는 것은 유전자 분석과 바이오마커 분석에 기반하여 치료 요법을 조정하는 맞춤형 의료 접근법입니다. 환자 모니터링과 순응도를 위한 디지털 헬스 툴의 통합은 치료 결과를 개선하고 있습니다.
또한, 남아있는 심혈관 위험에 대처하기 위해 여러 지질 경로를 표적으로 하는 병용요법이 널리 보급되고 있습니다. 경구제와 지속형 주사제의 개발로 환자의 편의성과 순응도가 향상되고 있습니다. 의료 인프라에 대한 투자가 활발히 이루어지고 있는 신흥시장에서는 고지혈증 치료에 대한 접근성이 확대되고 있습니다. 새로운 표적과 기전이 밝혀짐에 따라 고지혈증 치료제 시장은 진화할 것이며, 심혈관질환의 이환율과 사망률을 낮출 수 있는 혁신적인 치료제가 제공될 것입니다.
목차
제1장 서문
제2장 주요 요약
시장 하이라이트
세계 시장 현황
제3장 고지혈증 치료제 - 산업 분석
소개 : 시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
업계 동향
Porter's Five Forces 분석
시장 매력 분석
제4장 밸류체인 분석
밸류체인 분석
원재료 분석
원재료 리스트
원재료 제조업체 리스트
주요 원재료 가격 동향
잠재적 바이어 리스트
마케팅 채널
직접 마케팅
간접 마케팅
마케팅 채널 발전 동향
제5장 고지혈증 치료제 세계 시장 분석 : 유형별
유형별 개요
유형별, 과거 및 예측 데이터 분석
가족성
후천성
제6장 고지혈증 치료제 세계 시장 분석 : 약물 종류별
약물 종류별 개요
약물 종류별, 과거 및 예측 데이터 분석
스타틴
담즙산 분비 억제제
콜레스테롤 흡수 억제제
피브릭산 유도체
PCSK9 억제제
배합제
기타 약물 종류별
제7장 고지혈증 치료제 세계 시장 분석 : 투여 경로별
투여 경로별 개요
투여 경로별, 과거 및 예측 데이터 분석
경구
비경구
제8장 고지혈증 치료제 세계 시장 분석 : 유통 채널별
개요 : 유통 채널별
유통 채널별, 과거 및 예측 데이터 분석
병원 약국
소매 약국
온라인 약국
제9장 고지혈증 치료제 세계 시장 분석 : 지역별
지역별 전망
소개
북미 매출 분석
개요, 실적과 예측
북미 : 부문별
북미 국가별
미국
캐나다
멕시코
유럽 매출 분석
개요, 실적과 예측
유럽 : 부문별
유럽 국가별
영국
프랑스
독일
이탈리아
러시아
기타 유럽
아시아태평양 매출 분석
개요, 실적과 예측
아시아태평양 : 부문별
아시아태평양 국가별
중국
인도
일본
한국
호주
동남아시아
기타 아시아태평양
라틴아메리카 매출 분석
개요, 실적과 예측
라틴아메리카 : 부문별
라틴아메리카 국가별
브라질
아르헨티나
페루
칠레
기타 라틴아메리카
중동 및 아프리카 매출 분석
개요, 실적과 예측
중동 및 아프리카 : 부문별
중동 및 아프리카 국가별 리스트
사우디아라비아
아랍에미리트
이스라엘
남아프리카공화국
기타 중동 및 아프리카
제10장 고지혈증 치료제 기업 경쟁 구도
고지혈증 치료제 시장 경쟁
제휴, 협력, 합의
인수합병
신제품 출시
기타 개발
제11장 기업 개요
상위 기업의 시장 점유율 분석
시장 집중도
Johnson & Johnson
Roche
Pfizer
Novartis
Merck
Sanofi
Bristol Myers Squibb
AstraZeneca
GSK
Eli Lilly And Company
Amgen
Regeneron
Teva Pharmaceuticals
Sun Pharma
Dr. Reddy'S Laboratories
KSM
영문 목차
영문목차
Global Hyperlipidemia Drugs Market is poised to witness substantial growth, reaching a value of USD 36.33 Billion by the year 2033, up from USD 26.1 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 3.74% between 2025 and 2033.
The hyperlipidemia drugs market is set for significant expansion driven by rising prevalence of cardiovascular diseases and metabolic disorders worldwide. Advances in lipid-lowering therapies, including PCSK9 inhibitors, RNA-based therapeutics, and novel small molecules, are offering improved efficacy and safety profiles. Future growth will be supported by personalized medicine approaches that tailor treatment regimens based on genetic and biomarker analysis. The integration of digital health tools for patient monitoring and adherence is enhancing therapeutic outcomes.
Additionally, combination therapies targeting multiple lipid pathways are gaining traction to address residual cardiovascular risk. The development of oral formulations and long-acting injectables is improving patient convenience and compliance. Emerging markets with increasing healthcare infrastructure investments are expanding access to hyperlipidemia treatments. As research continues to uncover novel targets and mechanisms, the hyperlipidemia drugs market will evolve, delivering innovative therapies that reduce cardiovascular morbidity and mortality.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
LIST OF SEGMENTS COVERED
This section of the Hyperlipidemia Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Type
Familial
Acquired
By Drug Class
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Other Drug Classes
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
List of Companies Profiled in the report
Johnson & Johnson, Pfizer, Roche, Merck & Co., Novartis, Sanofi, AstraZeneca, GSK, Bristol Myers Squibb, Eli Lilly, Amgen, Teva Pharmaceuticals, Regeneron, Alnylam Pharmaceuticals, Sun Pharma
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.2 Market Attractiveness Analysis By Drug Class
3.7.3 Market Attractiveness Analysis By Route of Administration
3.7.4 Market Attractiveness Analysis By Distribution Channel
3.7.5 Market Attractiveness Analysis By Regions
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY TYPE
5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Familial Historic and Forecast Sales By Regions
5.4. Acquired Historic and Forecast Sales By Regions
6. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY DRUG CLASS
6.1. Overview By Drug Class
6.2. Historical and Forecast Data Analysis By Drug Class
6.3. Statins Historic and Forecast Sales By Regions
6.4. Bile Acid Sequestrants Historic and Forecast Sales By Regions
6.5. Cholesterol Absorption Inhibitors Historic and Forecast Sales By Regions
6.6. Fibric Acid Derivatives Historic and Forecast Sales By Regions
6.7. PCSK9 Inhibitors Historic and Forecast Sales By Regions
6.8. Combination Historic and Forecast Sales By Regions
6.9. Other Drug Classes Historic and Forecast Sales By Regions
7. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1. Overview By Route of Administration
7.2. Historical and Forecast Data Analysis By Route of Administration
7.3. Oral Historic and Forecast Sales By Regions
7.4. Parenteral Historic and Forecast Sales By Regions
8. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL
8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data Analysis By Distribution Channel
8.3. Hospital Pharmacy Historic and Forecast Sales By Regions
8.4. Retail Pharmacy Historic and Forecast Sales By Regions
8.5. Online Pharmacy Historic and Forecast Sales By Regions
9. GLOBAL HYPERLIPIDEMIA DRUGS MARKET ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
9.3.1 Overview, Historic and Forecast Data Sales Analysis
9.3.2 North America By Segment Sales Analysis
9.3.3 North America By Country Sales Analysis
9.3.4 United States Sales Analysis
9.3.5 Canada Sales Analysis
9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
9.4.1 Overview, Historic and Forecast Data Sales Analysis
9.4.2 Europe By Segment Sales Analysis
9.4.3 Europe By Country Sales Analysis
9.4.4 United Kingdom Sales Analysis
9.4.5 France Sales Analysis
9.4.6 Germany Sales Analysis
9.4.7 Italy Sales Analysis
9.4.8 Russia Sales Analysis
9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
9.5.1 Overview, Historic and Forecast Data Sales Analysis
9.5.2 Asia Pacific By Segment Sales Analysis
9.5.3 Asia Pacific By Country Sales Analysis
9.5.4 China Sales Analysis
9.5.5 India Sales Analysis
9.5.6 Japan Sales Analysis
9.5.7 South Korea Sales Analysis
9.5.8 Australia Sales Analysis
9.5.9 South East Asia Sales Analysis
9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
9.6.1 Overview, Historic and Forecast Data Sales Analysis
9.6.2 Latin America By Segment Sales Analysis
9.6.3 Latin America By Country Sales Analysis
9.6.4 Brazil Sales Analysis
9.6.5 Argentina Sales Analysis
9.6.6 Peru Sales Analysis
9.6.7 Chile Sales Analysis
9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
9.7.1 Overview, Historic and Forecast Data Sales Analysis
9.7.2 Middle East & Africa By Segment Sales Analysis
9.7.3 Middle East & Africa By Country Sales Analysis
9.7.4 Saudi Arabia Sales Analysis
9.7.5 UAE Sales Analysis
9.7.6 Israel Sales Analysis
9.7.7 South Africa Sales Analysis
9.7.8 Rest Of Middle East And Africa Sales Analysis
10. COMPETITIVE LANDSCAPE OF THE HYPERLIPIDEMIA DRUGS COMPANIES
10.1. Hyperlipidemia Drugs Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11. COMPANY PROFILES OF HYPERLIPIDEMIA DRUGS INDUSTRY
11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Johnson & Johnson
11.3.1 Company Overview
11.3.2 Company Revenue
11.3.3 Products
11.3.4 Recent Developments
11.4. Roche
11.4.1 Company Overview
11.4.2 Company Revenue
11.4.3 Products
11.4.4 Recent Developments
11.5. Pfizer
11.5.1 Company Overview
11.5.2 Company Revenue
11.5.3 Products
11.5.4 Recent Developments
11.6. Novartis
11.6.1 Company Overview
11.6.2 Company Revenue
11.6.3 Products
11.6.4 Recent Developments
11.7. Merck
11.7.1 Company Overview
11.7.2 Company Revenue
11.7.3 Products
11.7.4 Recent Developments
11.8. Sanofi
11.8.1 Company Overview
11.8.2 Company Revenue
11.8.3 Products
11.8.4 Recent Developments
11.9. Bristol Myers Squibb
11.9.1 Company Overview
11.9.2 Company Revenue
11.9.3 Products
11.9.4 Recent Developments
11.10. AstraZeneca
11.10.1 Company Overview
11.10.2 Company Revenue
11.10.3 Products
11.10.4 Recent Developments
11.11. GSK
11.11.1 Company Overview
11.11.2 Company Revenue
11.11.3 Products
11.11.4 Recent Developments
11.12. Eli Lilly And Company
11.12.1 Company Overview
11.12.2 Company Revenue
11.12.3 Products
11.12.4 Recent Developments
11.13. Amgen
11.13.1 Company Overview
11.13.2 Company Revenue
11.13.3 Products
11.13.4 Recent Developments
11.14. Regeneron
11.14.1 Company Overview
11.14.2 Company Revenue
11.14.3 Products
11.14.4 Recent Developments
11.15. Teva Pharmaceuticals
11.15.1 Company Overview
11.15.2 Company Revenue
11.15.3 Products
11.15.4 Recent Developments
11.16. Sun Pharma
11.16.1 Company Overview
11.16.2 Company Revenue
11.16.3 Products
11.16.4 Recent Developments
11.17. Dr. Reddy'S Laboratories
11.17.1 Company Overview
11.17.2 Company Revenue
11.17.3 Products
11.17.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies
